Illumina stock gains 7.95 percent as RBC raises target

Published on 10/05/2026 at 21:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Illumina stock traded at USD 294.74 on October 5, 2026, while RBC Capital lifted its target to USD 310. Q2 revenue rose 9.5 percent to USD 1.159 billion.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin beim Pipettieren im Genomiklabor — Illumina Inc. zeigt US4523271090 in dokumentarischer Schwarzweiß-Reportage einer Wissenschaftlerin beim Pipettieren im Labor, Illustration mit AI erstellt.

Illumina stock (ISIN US4523271090) was trading at USD 294.74 on Nasdaq on October 5, 2026, up 7.95 percent from the previous close, with the session high at USD 295.59 and the low at USD 271.61. The immediate catalyst was RBC Capital raising its price target from USD 230 to USD 310 while maintaining an Outperform rating, as MarketBeat reported on October 5, 2026.

RBC lifts target to USD 310

RBC's new target stands above the October 5 trading level and extends a series of upward revisions from Wall Street firms. StockAnalysis lists 21 analysts with a consensus rating of Buy, an average target of USD 214.6, a low of USD 113 and a high of USD 305 as of October 5, 2026. The split between the average target and the latest market price shows how sharply expectations have diverged from the current quotation.

Q2 growth supports the case

Illumina's latest reported quarter provides the operating basis for the target revisions. In its fiscal Q2 2026 release dated July 30, 2026, Illumina reported revenue of USD 1.159 billion, up 9.5 percent from USD 1.059 billion in Q2 2025. GAAP diluted EPS was USD 1.35, while non-GAAP diluted EPS reached USD 1.31, compared with USD 1.19 a year earlier.

The company also raised fiscal 2026 revenue guidance to USD 4.60 billion-USD 4.64 billion from USD 4.52 billion-USD 4.62 billion. Non-GAAP diluted EPS guidance increased to USD 5.30-USD 5.40 from USD 5.15-USD 5.30, while fiscal-year rest-of-world organic revenue growth guidance moved above 5 percent from a prior range of 2 percent-4 percent.

Stock reaches a new yearly high

The market move places Illumina near its 52-week high of USD 295.59, versus a 52-week low of USD 88.00. Trading volume stood at 2,542,107 shares on October 5, 2026, while the market capitalization was USD 44.6 billion.

For investors, the central question is whether clinical demand and sequencing consumables can sustain the higher growth assumptions. Illumina said fiscal Q2 demand for NovaSeq X remained high, and its latest guidance now implies a stronger second half than the earlier outlook.

Nasdaq valuation moves higher

Illumina stock was last at USD 294.74 on Nasdaq at 3:33 p.m. ET on October 5, 2026. The price and guidance reset now sit well above the company's fiscal Q2 operating base, making the next reported quarter the key test for the market's elevated expectations.